HomeStock ScreenerShukra Pharmaceuticals

Shukra Pharmaceuticals Share Price | Shukra Pharmaceuticals Stock Screener

SHUKRAPHAR Pharmaceuticals
Share Price BSE
₹28.09
▲ 0.86 (3.16%)
2026-05-27 00:00:00
As of May 27, 2026, the Shukra Pharmaceuticals share price (BSE: SHUKRAPHAR) is ₹28.09, up 3.16% from the previous close, with shares trading between ₹26.30 and ₹28.58, and a 52-week range of ₹12.97–₹64.43. Check SHUKRAPHAR price range for the annual price range and momentum. Use the Shukra Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Shukra Pharmaceuticals Market Cap ₹1,282.51 Cr.
SHUKRAPHAR P/E Ratio (TTM) 60.32
Shukra Pharmaceuticals P/B Ratio 14.70
EPS (TTM) ₹0.50
Dividend Yield -
Debt to Equity 0.06
SHUKRAPHAR 52 Week High ₹64.43
Shukra Pharmaceuticals 52 Week Low ₹12.97
Operating Margin 11.00%
Profit Margin -28.57%
SHUKRAPHAR Revenue (TTM) ₹7.00
EBITDA ₹2.00
Net Income ₹-2.00
Total Assets ₹117.00
Total Equity ₹90.00

Shukra Pharmaceuticals Share Price Chart

Screen Shukra Pharmaceuticals share price with an interactive chart. Analyse SHUKRAPHAR price trends and volatility across different timeframes.

Shukra Pharmaceuticals Company Profile - Fundamental Screener

Screen Shukra Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SHUKRAPHAR shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE551C01044

Shukra Pharmaceuticals Balance Sheet Screener

Screen SHUKRAPHAR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017
Assets
Total Assets 117 87 78 75 35 36 34 28 24 19
Current Assets 84 65 56 53 16 16 15 11 8 7
Fixed Assets 34 19 20 20 18 18 17 16 14 10
Liabilities
Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 5 7 6 7 6 13 11 9 6 3
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 90 63 58 25 16 16 15 15 15 15
Share Capital 44 44 11 4 2 2 2 2 2 2
Reserves & Surplus 46 19 47 21 15 14 14 14 13 13

Shukra Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Shukra Pharmaceuticals income statement and profit fundamentals. Analyze SHUKRAPHAR quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Shukra Pharmaceuticals share price evaluation.
Item 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec
Revenue 7 40 8 7 15 12
Expenses 6 12 6 4 6 7
EBITDA 2 28 1 2 9 5
Operating Profit % 11.00% 69.00% -7.00% 24.00% 55.00% 37.00%
Depreciation 1 1 1 1 1 1
Interest 0 0 0 0 0 0
Profit Before Tax 0 27 0 1 8 4
Tax 2 7 -2 0 2 1
Net Profit -2 20 2 1 5 3
EPS -0.04 0.47 0.05 0.02 0.12 0.72

Shukra Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen SHUKRAPHAR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March
Operating Activities 8 -5 3 8 1 1 0 1 0 3
Investing Activities -1 -1 -4 -2 -2 -3 -3 -5 -1 0
Financing Activities -5 12 5 -7 2 2 2 4 0 -1
Net Cash Flow 2 6 4 0 0 0 0 -1 -1 1

Shukra Pharmaceuticals Shareholding Pattern Screener

See Shukra Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Shukra Pharmaceuticals promoter holding and ownership changes for SHUKRAPHAR on TickJournal.
Item 2026-Mar 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept
Promoter Holding 50.96% 50.96% 50.96% 50.96% 50.96% 50.96% 50.96% 50.96%
FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 9.37% 9.29% 28.69% 9.20% 9.43% 9.79% 9.19% 9.25%
Other Holding 39.56% 39.64% 20.24% 39.72% 39.50% 39.14% 39.73% 39.68%
Shareholder Count 27,173 18,231 20,337 21,441 25,649 12,974 14,989 16,321

Shukra Pharmaceuticals Share Dividend Screener - Share Yield Analysis

Check Shukra Pharmaceuticals dividend history with payout and yield data. View Shukra Pharmaceuticals dividend details including ex-dates and amounts for SHUKRAPHAR stock.
Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.01 0.03%
2024-March ₹1.00 4.58%
2023-March ₹0.50 6.13%
2022-March ₹0.50 42.74%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.50 208.33%
2018-March ₹0.50 263.16%
2017-March ₹0.50 156.25%

Shukra Pharmaceuticals Stock Index Membership

See which indices include Shukra Pharmaceuticals stock. Check SHUKRAPHAR index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Shukra Pharmaceuticals is not part of any tracked indices.
Only major market indices are tracked in our system.

Shukra Pharmaceuticals Market Events Screener - Corporate Actions

Get Shukra Pharmaceuticals corporate actions including splits, bonuses, and buybacks. Check Shukra Pharmaceuticals stock events that may affect SHUKRAPHAR share price.
Announcement Date Record Date Event Type Information Price Impact
Dividend ₹ 0.01 /share 126.55%
Dividend ₹ 0.50 /share 253.33%
Dividend ₹ 0.50 /share 76.74%
Dividend ₹ 1.00 /share -40.51%
Annual General Meeting NA 5.63%
Annual General Meeting NA 34.10%
2026-05-07 2026-05-07 Quarterly Result Announcement NA 13.62%
2026-02-04 2026-02-04 Quarterly Result Announcement NA -7.11%
2025-11-13 2025-11-13 Quarterly Result Announcement NA -0.17%
2025-11-01 2025-11-01 Extraordinary General Meeting NA 19.04%
2025-08-13 2025-08-13 Quarterly Result Announcement NA -9.76%
2025-05-29 2025-05-29 Quarterly Result Announcement NA -5.08%
2025-03-21 2025-01-29 Split 1:10 0.00%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -9.64%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -6.35%

Shukra Pharmaceuticals Competitors Screener - Peer Comparison

Screen SHUKRAPHAR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 442,581 41.43 54,729 9.71% 10,980 54.75
Divis Laboratories 182,828 73.47 9,712 18.67% 2,191 66.48
Torrent Pharmaceuticals 151,833 66.60 11,539 6.99% 1,911 61.90
Cipla 113,025 29.32 27,712 -2.46% 3,783 61.92
Dr Reddys Laboratories 109,105 26.47 33,593 -0.44% 3,998 52.61
Zydus Life Science 104,543 20.35 26,720 13.65% 5,242 69.40
Lupin 104,288 19.51 27,488 19.98% 5,345 47.33
Mankind Pharma 102,351 53.58 14,278 12.03% 1,750 62.34
Aurobindo Pharma 85,000 25.77 32,346 9.43% 3,484 52.91
Laurus Labs 72,530 81.91 6,813 21.03% 884 77.10

Shukra Pharmaceuticals Company Announcements - News Screener

Screen SHUKRAPHAR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-05-09 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-05-07 Announcement under Regulation 30 (LODR)-Allotment -
2026-05-07 Compliances-Reg.24(A)-Annual Secretarial Compliance -
2026-05-07 Corporate Action-Board approves Dividend -
2026-05-07 Regulation 32 For Starement Of Deviation -
2026-05-07 Results For The Financial Year Ended March 31 2026 -
2026-05-07 Board Meeting Outcome for Outcome For The Board Meeting Dated 07.05.2026 For The Audited Financial Results For The Quarter And Year Ended March 2026 -
2026-04-29 Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A -
2026-04-29 Board Meeting Intimation for Audited Financial Result For The Quarter And Financial Year Ended On 31St March 2026 Along With The Auditors Report -
2026-04-08 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-03-20 Closure of Trading Window -
2026-03-16 Board Meeting Outcome for Independent Directors Meeting -
2026-03-06 Board Meeting Intimation for Independent Directors Meeting -
2026-02-05 Newspaper Publication Of Standalone And Consolidated Un-Audited Financial Results For Quarter And Nine Month Ended 31St December 2025 -
2026-02-04 Unaudited Financial Results For The Quarter Ended December 2025 -
2026-02-04 Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Held On Wednesday February 04 2026 -
2026-01-30 Update on board meeting -
2026-01-30 Board Meeting Intimation for Unaudited Financial Result For The Third Quarter Ended On 31 December 2025 Along With The Auditors Limited Review Report. -
2026-01-28 Announcement under Regulation 30 (LODR)-Allotment -
2026-01-28 Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On Today -